Novartis AG
XMUN:NOT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
Salesforce Inc
NYSE:CRM
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
HK |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
Economic Moat
Novartis has no economic moat
Patent protection keeps copies of individual Novartis medicines out temporarily, but it does not permanently prevent competitors from taking sales. Generic competition affecting medicines such as Entresto and Tasigna shows why successful products alone do not ensure lasting protection across the company.
Why Novartis has no moat
Protection expires product by product
Novartis holds valuable drug patents, but their expiration or successful legal challenges allow rivals to sell competing copies, so protection must be renewed through new medicines rather than inherited indefinitely.
Limited lock-in against generics
For Novartis medicines facing approved interchangeable generics, patients can receive the same clinical benefit without paying for the original brand, limiting the practical barriers to moving to a cheaper rival.
